Sac-TMT, Pembrolizumab, ChemoA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06966700

Conditions

Breast Neoplasms

Triple Negative Breast Neoplasms

HR Low-Positive/HER2-Negative Breast Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab tirumotecan

Pembrolizumab

Rescue Medication

Carboplatin

Paclitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-08-14.